GTx, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It develops selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone901-523-9700
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees21
Next Earnings DateN/A
OptionableOptionable
GTX (NASDAQ:GTXI) Frequently Asked Questions
What is GTX's stock symbol?
GTX trades on the NASDAQ under the ticker symbol "GTXI."
How were GTX's earnings last quarter?
GTx, Inc. (NASDAQ:GTXI) posted its earnings results on Thursday, November, 15th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by $0.09. View GTX's Earnings History.
Has GTX been receiving favorable news coverage?
Headlines about GTXI stock have trended extremely negative recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. GTX earned a news impact score of -4.6 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for GTX.
Who are some of GTX's key competitors?
Some companies that are related to GTX include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).
What other stocks do shareholders of GTX own?
Who are GTX's key executives?
GTX's management team includes the folowing people:
- Dr. Robert James Wills B.S., M.S., Ph.D., Exec. Chairman (Age 65)
- Mr. Marc S. Hanover, Co-Founder, CEO & Director (Age 56)
- Mr. Henry P. Doggrell, VP, Chief Legal Officer & Sec. (Age 70)
- Mr. Jason T. Shackelford, VP of Fin. & Accounting, Principal Financial & Accounting Officer and Corp. Controller (Age 44)
- Dr. Diane C. Young, VP & Chief Medical Officer (Age 62)
How big of a company is GTX?
GTX has a market capitalization of $0.00. The biopharmaceutical company earns $-38,420,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. GTX employs 21 workers across the globe.View Additional Information About GTX.
What is GTX's official website?
How can I contact GTX?
GTX's mailing address is 17 W Pontotoc Ave. Suite 100, MEMPHIS TN, 38103. The biopharmaceutical company can be reached via phone at 901-523-9700 or via email at [email protected]
MarketBeat Community Rating for GTX (NASDAQ GTXI)
MarketBeat's community ratings are surveys of what our community members think about GTX and other stocks. Vote "Outperform" if you believe GTXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GTXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
